vs
MAXCYTE, INC.（MXCT）与OmniAb, Inc.（OABI）财务数据对比。点击上方公司名可切换其他公司
OmniAb, Inc.的季度营收约是MAXCYTE, INC.的1.7倍（$8.4M vs $4.8M）。OmniAb, Inc.净利率更高（-169.3% vs -200.5%，领先31.2%）。MAXCYTE, INC.同比增速更快（-20.9% vs -22.5%）。MAXCYTE, INC.自由现金流更多（$-2.9M vs $-5.7M）。过去两年OmniAb, Inc.的营收复合增速更高（48.4% vs -7.4%）
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
OmniAb, Inc.是一家跨国生物技术企业，拥有专利转基因动物平台及全流程抗体发现解决方案，与全球制药和生物科技公司合作，加速肿瘤、自身免疫病等刚需医疗领域的全人源治疗抗体开发。
MXCT vs OABI — 直观对比
营收规模更大
OABI
是对方的1.7倍
$4.8M
营收增速更快
MXCT
高出1.5%
-22.5%
净利率更高
OABI
高出31.2%
-200.5%
自由现金流更多
MXCT
多$2.8M
$-5.7M
两年增速更快
OABI
近两年复合增速
-7.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8M | $8.4M |
| 净利润 | $-9.6M | $-14.2M |
| 毛利率 | — | — |
| 营业利润率 | -234.5% | -188.2% |
| 净利率 | -200.5% | -169.3% |
| 营收同比 | -20.9% | -22.5% |
| 净利润同比 | 9.4% | -8.5% |
| 每股收益（稀释后） | — | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MXCTOABI
| Q4 25 | $4.8M | $8.4M | ||
| Q3 25 | $4.6M | $2.2M | ||
| Q2 25 | $5.8M | $3.9M | ||
| Q1 25 | $5.7M | $4.2M | ||
| Q4 24 | $6.1M | $10.8M | ||
| Q3 24 | $5.6M | $4.2M | ||
| Q2 24 | $5.0M | $7.6M | ||
| Q1 24 | $5.6M | $3.8M |
净利润MXCTOABI
| Q4 25 | $-9.6M | $-14.2M | ||
| Q3 25 | $-12.4M | $-16.5M | ||
| Q2 25 | $-12.4M | $-15.9M | ||
| Q1 25 | $-10.3M | $-18.2M | ||
| Q4 24 | $-10.6M | $-13.1M | ||
| Q3 24 | $-11.6M | $-16.4M | ||
| Q2 24 | $-9.4M | $-13.6M | ||
| Q1 24 | $-9.5M | $-19.0M |
营业利润率MXCTOABI
| Q4 25 | -234.5% | -188.2% | ||
| Q3 25 | -307.4% | -810.2% | ||
| Q2 25 | -244.3% | -416.2% | ||
| Q1 25 | -214.1% | -453.6% | ||
| Q4 24 | -213.1% | -147.0% | ||
| Q3 24 | -250.4% | -473.7% | ||
| Q2 24 | -241.0% | -214.1% | ||
| Q1 24 | -219.8% | -593.3% |
净利率MXCTOABI
| Q4 25 | -200.5% | -169.3% | ||
| Q3 25 | -269.7% | -738.1% | ||
| Q2 25 | -212.2% | -407.4% | ||
| Q1 25 | -178.7% | -438.1% | ||
| Q4 24 | -175.0% | -121.0% | ||
| Q3 24 | -205.9% | -392.4% | ||
| Q2 24 | -188.8% | -179.0% | ||
| Q1 24 | -170.6% | -498.8% |
每股收益（稀释后）MXCTOABI
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-0.12 | $-0.14 | ||
| Q2 25 | $-0.12 | $-0.15 | ||
| Q1 25 | — | $-0.17 | ||
| Q4 24 | — | $-0.13 | ||
| Q3 24 | $-0.11 | $-0.16 | ||
| Q2 24 | $-0.09 | $-0.13 | ||
| Q1 24 | — | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.0M | $25.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $171.5M | $267.0M |
| 总资产 | $202.5M | $300.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MXCTOABI
| Q4 25 | $103.0M | $25.5M | ||
| Q3 25 | $105.7M | $28.5M | ||
| Q2 25 | $126.6M | $18.3M | ||
| Q1 25 | $138.3M | $10.9M | ||
| Q4 24 | $154.5M | $27.6M | ||
| Q3 24 | $153.8M | $27.2M | ||
| Q2 24 | $157.3M | $20.8M | ||
| Q1 24 | $157.5M | $19.1M |
股东权益MXCTOABI
| Q4 25 | $171.5M | $267.0M | ||
| Q3 25 | $180.3M | $277.4M | ||
| Q2 25 | $190.7M | $262.1M | ||
| Q1 25 | $199.4M | $273.5M | ||
| Q4 24 | $206.3M | $287.6M | ||
| Q3 24 | $213.3M | $291.7M | ||
| Q2 24 | $221.3M | $294.2M | ||
| Q1 24 | $226.4M | $301.4M |
总资产MXCTOABI
| Q4 25 | $202.5M | $300.9M | ||
| Q3 25 | $213.5M | $309.7M | ||
| Q2 25 | $219.8M | $295.7M | ||
| Q1 25 | $230.0M | $306.2M | ||
| Q4 24 | $239.5M | $325.6M | ||
| Q3 24 | $248.6M | $331.6M | ||
| Q2 24 | $251.5M | $337.3M | ||
| Q1 24 | $257.9M | $352.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.7M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | $-5.7M |
| 自由现金流率自由现金流/营收 | -61.0% | -67.8% |
| 资本支出强度资本支出/营收 | 4.8% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-36.2M | $-37.0M |
8季度趋势，按日历期对齐
经营现金流MXCTOABI
| Q4 25 | $-2.7M | $-5.7M | ||
| Q3 25 | $-7.5M | $-9.8M | ||
| Q2 25 | $-9.9M | $-5.1M | ||
| Q1 25 | $-14.4M | $-15.9M | ||
| Q4 24 | $-7.8M | $-3.9M | ||
| Q3 24 | $-4.4M | $-6.6M | ||
| Q2 24 | $-4.8M | $-12.2M | ||
| Q1 24 | $-10.6M | $-17.0M |
自由现金流MXCTOABI
| Q4 25 | $-2.9M | $-5.7M | ||
| Q3 25 | $-7.8M | $-9.9M | ||
| Q2 25 | $-10.4M | $-5.3M | ||
| Q1 25 | $-15.1M | $-16.1M | ||
| Q4 24 | $-8.0M | $-3.9M | ||
| Q3 24 | $-4.8M | $-6.7M | ||
| Q2 24 | $-5.1M | $-12.9M | ||
| Q1 24 | $-11.4M | $-18.0M |
自由现金流率MXCTOABI
| Q4 25 | -61.0% | -67.8% | ||
| Q3 25 | -168.5% | -444.2% | ||
| Q2 25 | -179.2% | -136.3% | ||
| Q1 25 | -262.3% | -387.1% | ||
| Q4 24 | -131.6% | -36.3% | ||
| Q3 24 | -85.5% | -161.3% | ||
| Q2 24 | -103.3% | -169.9% | ||
| Q1 24 | -203.6% | -472.5% |
资本支出强度MXCTOABI
| Q4 25 | 4.8% | 0.1% | ||
| Q3 25 | 6.5% | 8.1% | ||
| Q2 25 | 10.0% | 4.2% | ||
| Q1 25 | 11.4% | 5.0% | ||
| Q4 24 | 2.4% | 0.4% | ||
| Q3 24 | 7.2% | 3.6% | ||
| Q2 24 | 5.9% | 9.9% | ||
| Q1 24 | 14.4% | 24.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
